Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Haematopoietic Cell Transplantation: Extended Follow-Up of the Phase 2 Multi-Cohort CheckMate 205 Study

被引：0
|
作者：
Collins, G. [1 ]
Armand, P. [2 ]
Engert, A. [3 ]
Younes, A. [4 ]
Lee, H. J. [5 ]
Santoro, A. [6 ]
Zinzani, P. L. [7 ]
Timmerman, J. [8 ]
Ramchandren, R. [9 ]
Cohen, J. [10 ]
De Boer, J. P. [11 ]
Savage, K. [12 ]
Kuruvilla, J. [13 ,14 ]
Trneny, M. [15 ,16 ]
Shipp, M. [2 ]
Sacchi, M. [17 ]
Sumbul, A. [17 ]
Ansell, S. [18 ]
机构：
[1] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Hosp Cologne, Cologne, Germany
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Humanitas Univ, Humanitas Canc Ctr, Milan, Italy
[7] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy
[8] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA
[9] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[11] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[12] BC Canc, Vancouver, BC, Canada
[13] Univ Toronto, Vancouver, BC, Canada
[14] Princess Margaret Canc Ctr, Vancouver, BC, Canada
[15] Charles Univ Prague, Prague, Czech Republic
[16] Gen Univ Hosp Prague, Prague, Czech Republic
[17] Bristol Myers Squibb, Princeton, NJ USA
[18] Mayo Clin, Rochester, MN USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷
关键词：
checkpoint inhibitor; Hodgkin lymphoma; long-term outcomes; programmed death-1;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH19-PO-0
引用
收藏
页码：80 / 81
页数：2
相关论文
共 50 条
  • [21] Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
    Ansell, Stephen
    Broeckelmann, Paul
    von Keudell, Gottfried
    Lee, Hun Ju
    Santoro, Armando
    Zinzani, Pier Luigi
    Collins, Graham
    Cohen, Jonathon
    De Boer, Jan Paul
    Kuruvilla, John
    Savage, Kerry
    Trneny, Marek
    Provencio, Mariano
    Jaeger, Ulrich
    Willenbacher, Wolfgang
    Swanink, Rene
    Shipp, Margaret
    Engert, Andreas
    Armand, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S373 - S374
  • [22] Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study (vol 7, pg 6266, 2023)
    Ansell, S. M.
    Broeckelmann, P. J.
    von Keudell, G.
    BLOOD ADVANCES, 2024, 8 (04) : 829 - 831
  • [23] Lymphocyte recovery and survival after autologous haematopoietic stem cell transplantation in refractory and relapsed Hodgkin's lymphoma
    Czyz, A.
    Lojko, A.
    Gil, L.
    Nowicki, A.
    Dytfeld, D.
    Matuszak, M.
    Sawinski, K.
    Bembnista, E.
    Kozlowska, M.
    Komarnicki, M.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S253 - S254
  • [24] QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA TREATED WITH NIVOLUMAB MONOTHERAPY IN CHECKMATE 205 (COHORT B), A PHASE 2 STUDY
    Engert, A.
    Hirji, I.
    Taylor, F.
    Bennett, B.
    Cocks, K.
    Kato, K.
    Cella, D.
    HAEMATOLOGICA, 2016, 101 : 73 - 73
  • [25] NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: 2-YEAR FOLLOW-UP IN THE CHECKMATE 205 STUDY
    Domingo-Domenech, E.
    Ramchandren, R.
    Rueda, A.
    Trne
    Ny, M.
    Feldman, T.
    Hun, Lee J.
    Provencio, M.
    Sillaber, C.
    Cohen, J. B.
    Savage, K. J.
    Willenbacher, W.
    Sumbul, A.
    Sacchi, M.
    Armand, P.
    Ansell, S.
    HAEMATOLOGICA, 2019, 104 : 21 - 22
  • [26] A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma
    Shea, Lauren
    Watkins, Marcus P.
    Wan, Fei
    Cashen, Amanda F.
    Wagner-Johnston, Nina D.
    Jacoby, Meagan A.
    Abboud, Camille N.
    Dipersio, John F.
    Hurd, David D.
    Jaglowski, Samantha M.
    Bartlett, Nancy L.
    Fehniger, Todd A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (12) : 2223 - 2228
  • [27] PENPULIMAB FOR RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN'S LYMPHOMA (CHL): EXTENDED FOLLOW-UP OF THE MULTICENTER, SINGLE-ARM, PHASE 2 STUDY
    Song, Yuqin
    Zhou, Keshu
    Jin, Chuan
    Qian, Zhengzi
    Hou, Ming
    Fan, Lei
    Li, Fei
    Ding, Kaiyang
    Zhou, Hui
    Li, Xiaoling
    Chen, Bing
    Sun, Xiuhua
    Song, Xianmin
    Jiang, Ming
    Zhang, Qingyuan
    Liu, Lihong
    Yu, Guohua
    Hu, Yu
    Zhao, Zheng
    Liu, Ligen
    Xue, Hongwei
    Luo, Jun
    He, Bai
    Yao, Zhifang
    Xu, Fenghua
    Zhao, Min
    Li, Baiyong
    Xia, Yu
    Zhu, Jun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A598 - A598
  • [28] Nivolumab plus Doxorubicin, Vinblastine and Dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: CheckMate 205 Cohort D 2-year follow-up results
    Engert, A.
    Domingo-Domenech, E.
    Ramchandren, R.
    Rueda, A.
    Trneny, M.
    Feldman, T.
    Lee, H. J.
    Provencio, M.
    Sillaber, C.
    Cohen, J. B.
    Savage, K. J.
    Willenbacher, W.
    Sumbul, A.
    Sacchi, M.
    Armand, P.
    Ansell, S. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 162 - 162
  • [29] THE FREQUENCY OF RELAPSED OR REFRACTORY DISEASE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN CLASSICAL HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW
    Szabo, S. M.
    Roop, S.
    Juarez Garcia, A.
    Hirji, I
    VALUE IN HEALTH, 2016, 19 (07) : A715 - A715
  • [30] Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma—a long-term follow-up single center experience
    Malte Roerden
    Martin Sökler
    Lothar Kanz
    Wolfgang Bethge
    Wichard Vogel
    Juliane S. Walz
    Annals of Hematology, 2020, 99 : 265 - 276
12345